Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze RPRX stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate RPRX investment potential.

What is RPRX stock price today?

Get real-time RPRX stock price, historical data, and price charts on Financhill. Track RPRX performance with our advanced analysis tools.

Is RPRX a good investment?

Evaluate RPRX investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy RPRX stock?

To buy RPRX stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of RPRX?

View detailed market capitalization data and company valuation metrics for RPRX on our comprehensive analysis page.

What is the P/E ratio of RPRX?

Use our fundamental analysis tools to view RPRX P/E ratio and compare valuation metrics with industry peers.

What are RPRX earnings?

View RPRX earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Royalty Pharma Plc 10K Form

Buy

RPRX
Royalty Pharma Plc

Last Price:

$39.14

Seasonality Move:

6.41%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09	10Q	RPRX/Royalty Pharma Plc Quarterly
2023-11-08	10Q	RPRX/Royalty Pharma Plc Quarterly
2023-08-08	10Q	RPRX/Royalty Pharma Plc Quarterly
2023-05-09	10Q	RPRX/Royalty Pharma Plc Quarterly
2022-11-08	10Q	RPRX/Royalty Pharma Plc Quarterly
2022-08-04	10Q	RPRX/Royalty Pharma Plc Quarterly

Receive RPRX News And Ratings

See the #1 stock for the next 7 days that we like better than RPRX

RPRX Financial Statistics

Sales & Book Value

Annual Sales:	$2.3B
Cash Flow:	$-258.4M
Price / Cash Flow:	21.62
Annual Sales:	$14.95
Price / Book:	2.64

Profitability

EPS (TTM):	1.74870
Net Income (TTM):	$1.3B
Gross Margin:	$0
Return on Equity:	13.15%
Return on Assets:	7.11%

Royalty Pharma Plc Earnings Forecast

Key Royalty Pharma Plc Financial Ratios

The Gross Profit Margin over the past 20 years for RPRX is 0.00%.
The Selling, General & Administrative Expenses for RPRX have been equal to 10.46% of Gross Profit Margin.
The Research & Development expenses have been 0.09% of Revenue.
The Interest Expense is 16.95% of Operating Income.
The Net Earning history of RPRX is 58.79% of Total Revenues.
Per Share Earnings over the last 20 years have been positive in 8 years.

Royalty Pharma Plc Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Pharmaceuticals
Sector:	Health Care
Current Symbol:	RPRX
CUSIP:	G7709Q
Website:	royaltypharma.com

Debt

Debt-to-Equity Ratio:	1.4
Current Ratio:	3.48
Quick Ratio:	3.47

Price-to-Earnings

Trailing P/E Ratio:	20.71
Forward P/E Ratio:	7.86

RPRX Technical Analysis vs Fundamental Analysis

Buy

Royalty Pharma Plc (RPRX) is a Buy

Is Royalty Pharma Plc a Buy or a Sell?

Royalty Pharma Plc stock is rated a Buy

The current Royalty Pharma Plc [RPRX] share price is $39.60. The Score for RPRX is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.